{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T06:41:52Z","timestamp":1792564912111,"version":"4.5.0"},"reference-count":210,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Obes Rep"],"DOI":"10.1007\/s13679-026-00770-z","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T05:51:16Z","timestamp":1792561876000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Decoding the Safety Profile of GLP-1 Receptor Agonists: Facts, Myths, and Ongoing Controversies"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4338-4879","authenticated-orcid":false,"given":"Dimitris C.","family":"Kounatidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia G.","family":"Vallianou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Kouveletsou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paraskevi","family":"Kontrafouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios","family":"Stamatopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Rebelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanthia","family":"Diakoumopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Dalamaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"key":"770_CR1","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3390\/medsci13040269","volume":"13","author":"AA Lee","year":"2025","unstructured":"Lee AA, Khotina VA, Kashirskikh DA, Voronko OE, Gasanov VAO, Vasiliev AV. Incretin-Based Therapies Through the Decades: Molecular Innovations and Clinical Impact. Med Sci (Basel Switzerland). 2025;13:269. https:\/\/doi.org\/10.3390\/medsci13040269.","journal-title":"Med Sci (Basel Switzerland)"},{"key":"770_CR2","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1016\/j.jacc.2025.08.027","volume":"86","author":"M Galli","year":"2025","unstructured":"Galli M, Benenati S, Laudani C, Simeone B, Sarto G, Ortega-Paz L, et al. Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients. J Am Coll Cardiol. 2025;86:1805\u201319. https:\/\/doi.org\/10.1016\/j.jacc.2025.08.027.","journal-title":"J Am Coll Cardiol"},{"key":"770_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391:109\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2403347.","journal-title":"N Engl J Med"},{"key":"770_CR4","doi-asserted-by":"publisher","first-page":"e95632","DOI":"10.7759\/cureus.95632","volume":"17","author":"GS Zacharia","year":"2025","unstructured":"Zacharia GS, Gongati SR, Kharel A, Jacob A. Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. Narrative Rev Cureus. 2025;17:e95632. https:\/\/doi.org\/10.7759\/cureus.95632.","journal-title":"Narrative Rev Cureus"},{"key":"770_CR5","doi-asserted-by":"publisher","unstructured":"Kansakar U, Jankauskas SS, Pande S, Mone P, Varzideh F, Santulli G, Orforglipron. A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes. Int J Mol Sci. 2026;27. https:\/\/doi.org\/10.3390\/ijms27031409.","DOI":"10.3390\/ijms27031409"},{"issue":"Suppl 2","key":"770_CR6","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/dom.16364","volume":"27","author":"RW Thomsen","year":"2025","unstructured":"Thomsen RW, Mailhac A, L\u00f8hde JB, Potteg\u00e5rd A. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes Obes Metab. 2025;27(Suppl 2):66\u201388. https:\/\/doi.org\/10.1111\/dom.16364.","journal-title":"Diabetes Obes Metab"},{"key":"770_CR7","doi-asserted-by":"publisher","unstructured":"Volkow ND, Xu R. Glucagon-Like Peptide-1 Receptor Agonists in Psychiatry: A Pharmacoepidemiological Scoping Review. Biol Psychiatry. 2026;S0006. https:\/\/doi.org\/10.1016\/j.biopsych.2026.03.1002. -3223(26)01132-7.","DOI":"10.1016\/j.biopsych.2026.03.1002"},{"key":"770_CR8","doi-asserted-by":"publisher","first-page":"24433","DOI":"10.1038\/s41598-024-75965-2","volume":"14","author":"E Kornelius","year":"2024","unstructured":"Kornelius E, Huang J-Y, Lo S-C, Huang C-N, Yang Y-S. The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy. Sci Rep. 2024;14:24433. https:\/\/doi.org\/10.1038\/s41598-024-75965-2.","journal-title":"Sci Rep"},{"key":"770_CR9","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/s41380-025-03261-0","volume":"31","author":"C-D Llach","year":"2026","unstructured":"Llach C-D, Badulescu S, Tabassum A, Shah H, Gill H, Le GH, et al. Glucagon-like Peptide-1 receptor agonists as emerging therapeutics in bipolar disorder: a narrative review of preclinical and clinical evidence. Mol Psychiatry. 2026;31:456\u201379. https:\/\/doi.org\/10.1038\/s41380-025-03261-0.","journal-title":"Mol Psychiatry"},{"key":"770_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/ph17020147","author":"R Ruggiero","year":"2024","unstructured":"Ruggiero R, Mascolo A, Spezzaferri A, Carpentieri C, Torella D, Sportiello L, Rossi F, Paolisso G, Capuano A. Pharmaceuticals (Basel). 2024;17(2):147. https:\/\/doi.org\/10.3390\/ph17020147. Glucagon-like Peptide-1 Receptor Agonists and Suicidal Ideation: Analysis of Real-Word Data Collected in the European Pharmacovigilance Database."},{"key":"770_CR11","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jpsychires.2025.02.008","volume":"183","author":"K Valentino","year":"2025","unstructured":"Valentino K, Teopiz KM, Cheung W, Wong S, Le GH, Rosenblat JD, et al. The effect of glucagon-like Peptide-1 receptor agonists on measures of suicidality: A systematic review. J Psychiatr Res. 2025;183:112\u201326. https:\/\/doi.org\/10.1016\/j.jpsychires.2025.02.008.","journal-title":"J Psychiatr Res"},{"key":"770_CR12","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamapsychiatry.2025.0679","volume":"82","author":"ACS Pierret","year":"2025","unstructured":"Pierret ACS, Mizuno Y, Saunders P, Lim E, De Giorgi R, Howes OD, et al. Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2025;82:643\u201353. https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.0679.","journal-title":"JAMA Psychiatry"},{"key":"770_CR13","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1001\/jamapsychiatry.2025.0091","volume":"82","author":"P Ebrahimi","year":"2025","unstructured":"Ebrahimi P, Batlle JC, Ayati A, Maqsood MH, Long C, Tarabanis C, et al. Suicide and Self-Harm Events With GLP-1 Receptor Agonists in Adults With Diabetes or Obesity: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2025;82:888\u201395. https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.0091.","journal-title":"JAMA Psychiatry"},{"key":"770_CR14","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","volume":"30","author":"W Wang","year":"2024","unstructured":"Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat Med. 2024;30:168\u201376. https:\/\/doi.org\/10.1038\/s41591-023-02672-2.","journal-title":"Nat Med"},{"key":"770_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70985","author":"C Kim","year":"2026","unstructured":"Kim C, Kim S, Lee DY, Han E, Lee Y-H, You SC. Glucagon-Like Peptide-1 Receptor Agonists and Risk of Mental Health Disorders in Type 2 Diabetes: Active Comparator, New User Cohort Study. Diabetes Obes Metab. 2026. https:\/\/doi.org\/10.1111\/dom.70985.","journal-title":"Diabetes Obes Metab"},{"key":"770_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/dom.71088","author":"SC-C Chen","year":"2026","unstructured":"Chen SC-C, Wang T-J, Chou C-K, Lee C. Neuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other GLP-1 Receptor Agonists. Diabetes Obes Metab. 2026. https:\/\/doi.org\/10.1111\/dom.71088.","journal-title":"Diabetes Obes Metab"},{"key":"770_CR17","doi-asserted-by":"publisher","first-page":"1869086","DOI":"10.3389\/fnsyn.2026.1869086","volume":"18","author":"MM Borovcanin","year":"2026","unstructured":"Borovcanin MM, Petrovic I. Suicidality as a potential risk and therapeutic target during widespread GLP-1 receptor agonists use: implications of inflammation. Front Synaptic Neurosci. 2026;18:1869086. https:\/\/doi.org\/10.3389\/fnsyn.2026.1869086.","journal-title":"Front Synaptic Neurosci"},{"key":"770_CR18","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/dom.70198","volume":"28","author":"B Sa","year":"2026","unstructured":"Sa B, Maristany A, Subramaniam A, Guillen R, Buonocore B, Smith A, et al. Psychiatric effects of GLP-1 receptor agonists: A systematic review of emerging evidence. Diabetes Obes Metab. 2026;28:50\u20139. https:\/\/doi.org\/10.1111\/dom.70198.","journal-title":"Diabetes Obes Metab"},{"key":"770_CR19","doi-asserted-by":"publisher","first-page":"S163","DOI":"10.1192\/j.eurpsy.2025.411","volume":"68","author":"A Stewart","year":"2025","unstructured":"Stewart A, Carr B. Theoretical Mechanisms of GLP-1 Receptor Agonist-Induced Depression in Obesity Treatment. Eur Psychiatry. 2025;68:S163\u20134. https:\/\/doi.org\/10.1192\/j.eurpsy.2025.411.","journal-title":"Eur Psychiatry"},{"key":"770_CR20","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.chom.2026.05.003","volume":"34","author":"L Bian","year":"2026","unstructured":"Bian L, Cai Y, Zhang Y, Shen L, Wang H, Gao F, et al. Microbiota-driven gut-brain signaling underlies antidepressant effects of a GLP-1 analog. Cell Host Microbe. 2026;34:1000\u2013e10175. https:\/\/doi.org\/10.1016\/j.chom.2026.05.003.","journal-title":"Cell Host Microbe"},{"key":"770_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-026-04244-7","author":"G Yang","year":"2026","unstructured":"Yang G, Burgess S, Schooling CM. Glucagon-like peptide-1 receptor activation and mental health: a drug-target mendelian randomization study. Transl Psychiatry. 2026. https:\/\/doi.org\/10.1038\/s41398-026-04244-7.","journal-title":"Transl Psychiatry"},{"key":"770_CR22","unstructured":"https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2024 n.d. (assessed on 10 July 2026)."},{"key":"770_CR23","unstructured":"https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type n.d. (assessed on 10 July 2026)."},{"key":"770_CR24","doi-asserted-by":"publisher","first-page":"7048","DOI":"10.1111\/dom.70927","volume":"28","author":"Y Chang","year":"2026","unstructured":"Chang Y, Hsieh M-H, Ju P-C, Chang C-C. Risk of Psychiatric Worsening With GLP-1 Receptor Agonist Use in Patients With Type 2 Diabetes and Treated Depression. Diabetes Obes Metab. 2026;28:7048\u201357. https:\/\/doi.org\/10.1111\/dom.70927.","journal-title":"Diabetes Obes Metab"},{"key":"770_CR25","doi-asserted-by":"publisher","unstructured":"Xiang L, Peng Y. Impact of Glucagon-like Peptide-1 Receptor Agonists on Mental Illness: Evidence from a Mendelian Randomization Study. Int J Mol Sci. 2025;26. https:\/\/doi.org\/10.3390\/ijms26062741.","DOI":"10.3390\/ijms26062741"},{"key":"770_CR26","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.clinthera.2026.02.010","volume":"48","author":"I Choudhury","year":"2026","unstructured":"Choudhury I, Ward JH, Mahesh S, Alam U, Azmi S, Anson M. Effect of Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) on Neuropsychiatric Outcomes: A Systematic Review and Meta-Analysis. Clin Ther. 2026;48:347\u201384. https:\/\/doi.org\/10.1016\/j.clinthera.2026.02.010.","journal-title":"Clin Ther"},{"key":"770_CR27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/dom.70175","volume":"28","author":"Y Chang","year":"2026","unstructured":"Chang Y, Hsieh M-H, Ju P-C, Chang C-C. Risk of depression with GLP-1 receptor agonists use in overweight or obese adults with type 2 diabetes: A new-user, active-comparator cohort study. Diabetes Obes Metab. 2026;28:197\u2013209. https:\/\/doi.org\/10.1111\/dom.70175.","journal-title":"Diabetes Obes Metab"},{"key":"770_CR28","doi-asserted-by":"publisher","unstructured":"Lixi F, Troisi M, Calabresi V, Giagoni A, Rossi C, Timofte-Zorila M-M, et al. Beyond Glycemic Control: Ocular Effects of Glucagon-like Peptide-1 Receptor Agonists. Vis (Basel Switz. 2026;10. https:\/\/doi.org\/10.3390\/vision10020029.","DOI":"10.3390\/vision10020029"},{"key":"770_CR29","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1607141.","journal-title":"N Engl J Med"},{"key":"770_CR30","doi-asserted-by":"publisher","first-page":"4386","DOI":"10.1111\/dom.15788","volume":"26","author":"DS-H Lin","year":"2024","unstructured":"Lin DS-H, Lo H-Y, Huang K-C, Lin T-T, Lee J-K, Lin L-Y. Incidence and progression of diabetic retinopathy in patients treated with glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: A population-based cohort study. Diabetes Obes Metab. 2024;26:4386\u201396. https:\/\/doi.org\/10.1111\/dom.15788.","journal-title":"Diabetes Obes Metab"},{"key":"770_CR31","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375:311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603827.","journal-title":"N Engl J Med"},{"key":"770_CR32","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet (London England). 2019;394:121\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3.","journal-title":"Lancet (London England)"},{"key":"770_CR33","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1007\/s00125-025-06466-8","volume":"68","author":"AJ Buckley","year":"2025","unstructured":"Buckley AJ, Tan GD, Gruszka-Goh M, Scanlon PH, Ansari I, Suliman SGI. Early worsening of diabetic retinopathy in individuals with type 2 diabetes treated with tirzepatide: a real-world cohort study. Diabetologia. 2025;68:2069\u201376. https:\/\/doi.org\/10.1007\/s00125-025-06466-8.","journal-title":"Diabetologia"},{"key":"770_CR34","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.ophtha.2026.01.013","volume":"133","author":"J Shah","year":"2026","unstructured":"Shah J, Razavi P, Festok M, Ahmed H, Mahrous MA, Kovacs KD, et al. Tirzepatide and Reduced Risk of Diabetic Retinopathy and Related Complications: A Multicenter US Cohort Study. Ophthalmology. 2026;133:728\u201332. https:\/\/doi.org\/10.1016\/j.ophtha.2026.01.013.","journal-title":"Ophthalmology"},{"key":"770_CR35","doi-asserted-by":"publisher","unstructured":"Xu J, Ashebir YA, Shao Y. Molecular Basis of Synergistic Causal Effect of Dual GLP-1R and GIPR Agonists for Risk Reduction in Diabetic Retinopathy, Alzheimer Disease, and Coronary Artery Disease in Diabetic Patients. Genes (Basel). 2026;17. https:\/\/doi.org\/10.3390\/genes17060602.","DOI":"10.3390\/genes17060602"},{"key":"770_CR36","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/dom.13538","volume":"21","author":"SC Bain","year":"2019","unstructured":"Bain SC, Klufas MA, Ho A, Matthews DR. Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review. Diabetes Obes Metab. 2019;21:454\u201366. https:\/\/doi.org\/10.1111\/dom.13538.","journal-title":"Diabetes Obes Metab"},{"key":"770_CR37","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3390\/diabetology6100117","volume":"6","author":"G Albanese","year":"2025","unstructured":"Albanese G, Visioli G, Alisi L, Giovannetti F, Lucchino L, Armentano M, et al. Ocular effects of GLP-1 receptor agonists: a review of current evidence and safety concerns. Diabetology. 2025;6:117.","journal-title":"Diabetology"},{"key":"770_CR38","doi-asserted-by":"publisher","first-page":"7085","DOI":"10.1111\/dom.70107","volume":"27","author":"X Cheng","year":"2025","unstructured":"Cheng X, Fu Z, Chen Y, Wang J, Han F. Semaglutide attenuates diabetic retinopathy progression via ameliorating retinal vasculopathy and oxidative stress in vivo and in vitro. Diabetes Obes Metab. 2025;27:7085\u201396. https:\/\/doi.org\/10.1111\/dom.70107.","journal-title":"Diabetes Obes Metab"},{"key":"770_CR39","doi-asserted-by":"publisher","unstructured":"Anastasiou IA, Tentolouris A, Sarantis P, Katsaouni A, Rebelos E, Mourouzis I, et al. Semaglutide Enhances Cellular Regeneration in Skin and Retinal Cells In Vitro. Pharmaceutics. 2025;17. https:\/\/doi.org\/10.3390\/pharmaceutics17091115.","DOI":"10.3390\/pharmaceutics17091115"},{"key":"770_CR40","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/JCMA.0000000000001370","volume":"89","author":"T-E Wu","year":"2026","unstructured":"Wu T-E, Chen H-S. Ocular complications from glucagon-like peptide-1 receptor agonists: Clinical evidence, potential mechanisms, and clinical recommendations. J Chin Med Assoc. 2026;89:407\u201314. https:\/\/doi.org\/10.1097\/JCMA.0000000000001370.","journal-title":"J Chin Med Assoc"},{"key":"770_CR41","doi-asserted-by":"publisher","first-page":"724","DOI":"10.2337\/dc25-1238","volume":"49","author":"A Nogueira","year":"2026","unstructured":"Nogueira A, Rassi TNO, Iqbal A, Felix N, Alghaith O, Khan A, et al. Association Between GLP-1 Receptor Agonists and Ischemic Optic Neuropathy: A Meta-analysis. Diabetes Care. 2026;49:724\u20139. https:\/\/doi.org\/10.2337\/dc25-1238.","journal-title":"Diabetes Care"},{"key":"770_CR42","doi-asserted-by":"publisher","DOI":"10.1111\/aos.70168","author":"S Niazi","year":"2026","unstructured":"Niazi S, Gnesin F, Jawad BN, Niazi Z, Yazdanfard PDW, Toft-Petersen AP, et al. Timing and duration of glucagon-like peptide-1 receptor agonist use and risk of nonarteritic anterior ischaemic optic neuropathy. Acta Ophthalmol. 2026. https:\/\/doi.org\/10.1111\/aos.70168.","journal-title":"Acta Ophthalmol"},{"key":"770_CR43","doi-asserted-by":"publisher","first-page":"119635","DOI":"10.1016\/j.biopha.2026.119635","volume":"201","author":"YK Lee","year":"2026","unstructured":"Lee YK, Chang YY, Jang HN, Ma DJ, Song HB. GLP-1 receptor agonist-induced transient retinal perfusion delay and its potential mediation by intracranial pressure. Biomed Pharmacother. 2026;201:119635. https:\/\/doi.org\/10.1016\/j.biopha.2026.119635.","journal-title":"Biomed Pharmacother"},{"key":"770_CR44","doi-asserted-by":"publisher","first-page":"1808359","DOI":"10.3389\/fphar.2026.1808359","volume":"17","author":"A Anatriello","year":"2026","unstructured":"Anatriello A, Liguori V, Cagnotta C, Pentella C, Scavone C, Capuano A, et al. Ocular disorders during treatment with GLP-1 receptor agonists: a systematic review and meta-analysis of observational studies. Front Pharmacol. 2026;17:1808359. https:\/\/doi.org\/10.3389\/fphar.2026.1808359.","journal-title":"Front Pharmacol"},{"key":"770_CR45","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ajo.2025.02.025","volume":"274","author":"NJ Abbass","year":"2025","unstructured":"Abbass NJ, Nahlawi R, Shaia JK, Allan KC, Kaelber DC, Talcott KE, et al. The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy. Am J Ophthalmol. 2025;274:24\u201331. https:\/\/doi.org\/10.1016\/j.ajo.2025.02.025.","journal-title":"Am J Ophthalmol"},{"key":"770_CR46","doi-asserted-by":"publisher","first-page":"526","DOI":"10.2337\/dc25-1929","volume":"49","author":"H-Y Li","year":"2026","unstructured":"Li H-Y, Chan T-K, Co Shih K, Cheung BMY, Yiu K-H, Tse H-F, et al. GLP-1 Receptor Agonists and Risk of Optic Nerve or Vision-Threatening Events in Patients With Type 2 Diabetes or Cardiometabolic Diseases: A Meta-analysis of Randomized Controlled Trials. Diabetes Care. 2026;49:526\u201335. https:\/\/doi.org\/10.2337\/dc25-1929.","journal-title":"Diabetes Care"},{"key":"770_CR47","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.ophtha.2026.04.008","volume":"133","author":"SW DeParis","year":"2026","unstructured":"DeParis SW, Oke I, Gaier ED, Moss HE, MacIntosh PW, Gilbert AL, et al. Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Consensus Statement by the North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology. Ophthalmology. 2026;133:1029\u201335. https:\/\/doi.org\/10.1016\/j.ophtha.2026.04.008.","journal-title":"Ophthalmology"},{"key":"770_CR48","doi-asserted-by":"publisher","first-page":"S261","DOI":"10.2337\/dc26-S012","volume":"49","author":"12","year":"2026","unstructured":"12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49:S261\u201376. https:\/\/doi.org\/10.2337\/dc26-S012.","journal-title":"Diabetes Care"},{"key":"770_CR49","doi-asserted-by":"publisher","first-page":"316","DOI":"10.2337\/cd19-0001","volume":"37","author":"RH Eckel","year":"2019","unstructured":"Eckel RH, Farooki A, Henry RR, Koch GG, Leiter LA. Cardiovascular Outcome Trials in Type 2 Diabetes: What Do They Mean for Clinical Practice? Clin Diabetes. 2019;37:316\u201337. https:\/\/doi.org\/10.2337\/cd19-0001.","journal-title":"Clin Diabetes"},{"key":"770_CR50","doi-asserted-by":"publisher","unstructured":"Robinson LE, Holt TA, Rees K, Randeva HS, O\u2019Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open. 2013;3. https:\/\/doi.org\/10.1136\/bmjopen-2012-001986.","DOI":"10.1136\/bmjopen-2012-001986"},{"key":"770_CR51","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, K\u00f8ber LV, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015;373:2247\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1509225.","journal-title":"N Engl J Med"},{"key":"770_CR52","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017;377:1228\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1612917.","journal-title":"N Engl J Med"},{"key":"770_CR53","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S2213-8587(25)00226-8","volume":"13","author":"S Wharton","year":"2025","unstructured":"Wharton S, Freitas P, Hjelmes\u00e6th J, Kabisch M, Kandler K, Lingvay I, et al. Once-weekly semaglutide 7\u00b72\u00a0mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13:949\u201363. https:\/\/doi.org\/10.1016\/S2213-8587(25)00226-8.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"770_CR54","doi-asserted-by":"publisher","first-page":"H235","DOI":"10.1152\/ajpheart.00809.2024","volume":"328","author":"GJ Grosicki","year":"2025","unstructured":"Grosicki GJ, Kim J, Fielding F, Jasinski SR, Chapman C, von Hippel W, et al. Heart and health behavior responses to GLP-1 receptor agonists: a 12-wk study using wearable technology and causal inference. Am J Physiol Heart Circ Physiol. 2025;328:H235\u201341. https:\/\/doi.org\/10.1152\/ajpheart.00809.2024.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"770_CR55","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12933-016-0490-6","volume":"16","author":"M Lorenz","year":"2017","unstructured":"Lorenz M, Lawson F, Owens D, Raccah D, Roy-Duval C, Lehmann A, et al. Differential effects of glucagon-like peptide-1 receptor agonists on heart rate. Cardiovasc Diabetol. 2017;16:6. https:\/\/doi.org\/10.1186\/s12933-016-0490-6.","journal-title":"Cardiovasc Diabetol"},{"key":"770_CR56","doi-asserted-by":"publisher","DOI":"10.1093\/ejhf\/xuag114","author":"FH Fussing","year":"2026","unstructured":"Fussing FH, Davodian LW, Davodian DW, Johansen ND, Kumarathurai P, Modin D, et al. Hemodynamic Changes in Response to GLP-1 Treatment in ICD and CRT Patients: Insights From HeartLogic Sensor Data. Eur J Heart Fail. 2026. https:\/\/doi.org\/10.1093\/ejhf\/xuag114.","journal-title":"Eur J Heart Fail"},{"key":"770_CR57","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s40001-026-03933-9","volume":"31","author":"Y Zhang","year":"2026","unstructured":"Zhang Y, Zhang C, Gong X, Cheng P, Fu H, Diao L, et al. Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis of randomized controlled trials. Eur J Med Res. 2026;31:318. https:\/\/doi.org\/10.1186\/s40001-026-03933-9.","journal-title":"Eur J Med Res"},{"key":"770_CR58","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(26)00202-3","volume":"407","author":"J Rosenstock","year":"2026","unstructured":"Rosenstock J, Yabe D, Cox D, Li J, Denning M, Wu W-S, et al. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. Lancet (London England). 2026;407:1147\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(26)00202-3.","journal-title":"Lancet (London England)"},{"key":"770_CR59","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1093\/cvr\/cvq271","volume":"89","author":"KJ Griffioen","year":"2011","unstructured":"Griffioen KJ, Wan R, Okun E, Wang X, Lovett-Barr MR, Li Y, et al. GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons. Cardiovasc Res. 2011;89:72\u20138. https:\/\/doi.org\/10.1093\/cvr\/cvq271.","journal-title":"Cardiovasc Res"},{"key":"770_CR60","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1093\/cvr\/cvae120","volume":"120","author":"AF Lubberding","year":"2024","unstructured":"Lubberding AF, Veedfald S, Achter JS, Nissen SD, Soattin L, Sorrentino A, et al. Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node. Cardiovasc Res. 2024;120:1427\u201341. https:\/\/doi.org\/10.1093\/cvr\/cvae120.","journal-title":"Cardiovasc Res"},{"key":"770_CR61","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.molmet.2017.08.010","volume":"6","author":"LL Baggio","year":"2017","unstructured":"Baggio LL, Ussher JR, McLean BA, Cao X, Kabir MG, Mulvihill EE, et al. The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice. Mol Metab. 2017;6:1339\u201349. https:\/\/doi.org\/10.1016\/j.molmet.2017.08.010.","journal-title":"Mol Metab"},{"key":"770_CR62","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1016\/j.jacc.2026.02.5083","volume":"87","author":"MS Khan","year":"2026","unstructured":"Khan MS, Javaid SS, Petrie MC, Zieroth S, Anker SD, Butler J. Obesity and Heart Failure With Reduced Ejection Fraction: A Review. J Am Coll Cardiol. 2026;87:3035\u201353. https:\/\/doi.org\/10.1016\/j.jacc.2026.02.5083.","journal-title":"J Am Coll Cardiol"},{"key":"770_CR63","doi-asserted-by":"publisher","unstructured":"Ahuja A, Prasad S, Manoharan S, Sen A, Rana R, Mody M, et al. Pulmonary adverse events associated with GLP-1 receptor agonists: a systematic review of respiratory safety signals. Cardiovasc Diabetol Endocrinol Rep. 2026;12. https:\/\/doi.org\/10.1186\/s40842-026-00311-6.","DOI":"10.1186\/s40842-026-00311-6"},{"key":"770_CR64","doi-asserted-by":"publisher","first-page":"e264722","DOI":"10.1001\/jamanetworkopen.2026.4722","volume":"9","author":"K Yang","year":"2026","unstructured":"Yang K, Liu C, Guo Q, Li Y. GLP-1 Receptor Agonists and Noncardiometabolic Outcomes: An Umbrella Review of Meta-Analyses. JAMA Netw Open. 2026;9:e264722. https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.4722.","journal-title":"JAMA Netw Open"},{"key":"770_CR65","doi-asserted-by":"publisher","first-page":"106645","DOI":"10.1016\/j.jinf.2025.106645","volume":"91","author":"S Han","year":"2025","unstructured":"Han S, Liu Y, Xing B, Yang Y, Liu Z, Li Y, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of infections: A systematic review and meta-analysis. J Infect. 2025;91:106645. https:\/\/doi.org\/10.1016\/j.jinf.2025.106645.","journal-title":"J Infect"},{"key":"770_CR66","doi-asserted-by":"publisher","first-page":"bvaf088","DOI":"10.1210\/jendso\/bvaf088","volume":"9","author":"CN Ho","year":"2025","unstructured":"Ho CN, Ayers AT, Kohn MA, Umpierrez GE, Klonoff DC. Glucagon-Like Peptide-1 Receptor Agonists and Peri-Procedural Aspiration Risk. J Endocr Soc. 2025;9:bvaf088. https:\/\/doi.org\/10.1210\/jendso\/bvaf088.","journal-title":"J Endocr Soc"},{"key":"770_CR67","doi-asserted-by":"publisher","DOI":"10.1136\/jnis-2026-025486","author":"S Sardana","year":"2026","unstructured":"Sardana S, Mateti N, Hackett CT, Singh R, Bagga S, Kotekal D, et al. GLP-1 receptor agonist use and aspiration pneumonia risk following endovascular thrombectomy. J Neurointerv Surg. 2026. https:\/\/doi.org\/10.1136\/jnis-2026-025486.","journal-title":"J Neurointerv Surg"},{"key":"770_CR68","doi-asserted-by":"publisher","first-page":"e00321","DOI":"10.1097\/XCE.0000000000000321","volume":"14","author":"A Shankar","year":"2025","unstructured":"Shankar A, Sharma A, Vinas A, Chilton RJ. GLP-1 receptor agonists and delayed gastric emptying: implications for invasive cardiac interventions and surgery. Cardiovasc Endocrinol Metab. 2025;14:e00321. https:\/\/doi.org\/10.1097\/XCE.0000000000000321.","journal-title":"Cardiovasc Endocrinol Metab"},{"key":"770_CR69","doi-asserted-by":"publisher","unstructured":"Kazi MAI, Kamal H, Mufarrih SM, Qureshi I, Singh S, Mazer A. Glucagon-like Peptide-1 Receptor Agonist Therapy and Risk of Pulmonary and Systemic Infections in Diabetic Gastroparesis: A Propensity-Matched Cohort Study. Adv Respir Med. 2026;94. https:\/\/doi.org\/10.3390\/arm94020020.","DOI":"10.3390\/arm94020020"},{"key":"770_CR70","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/anae.16601","volume":"80","author":"J Elkin","year":"2025","unstructured":"Elkin J, Rele S, Sumithran P, Hii M, Thuraisingam S, Spelman T, et al. Association between glucagon-like peptide-1 receptor agonist use and peri-operative pulmonary aspiration: a systematic review and meta-analysis. Anaesthesia. 2025;80:846\u201358. https:\/\/doi.org\/10.1111\/anae.16601.","journal-title":"Anaesthesia"},{"key":"770_CR71","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.bja.2025.08.003","volume":"136","author":"H-L Wu","year":"2026","unstructured":"Wu H-L, Chen J-T, Cata JP, Hsieh C-H, Cherng Y-G, Tai Y-H. Risk of perioperative cardiorespiratory complications and mortality associated with preoperative glucagon-like peptide-1 receptor agonist use in type 2 diabetes mellitus: a nationwide propensity-score matched study. Br J Anaesth. 2026;136:86\u201397. https:\/\/doi.org\/10.1016\/j.bja.2025.08.003.","journal-title":"Br J Anaesth"},{"key":"770_CR72","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10620-025-09307-1","volume":"71","author":"M Stryelkina","year":"2026","unstructured":"Stryelkina M, Molina R, Janice T, Ancha A, Bejcek J, Ian F, et al. Aspiration Risk During Endoscopic Procedures While on GLP-1 Agonist Therapy. Dig Dis Sci. 2026;71:211\u201320. https:\/\/doi.org\/10.1007\/s10620-025-09307-1.","journal-title":"Dig Dis Sci"},{"key":"770_CR73","doi-asserted-by":"publisher","first-page":"5135","DOI":"10.1007\/s00464-025-11962-4","volume":"39","author":"A Abdulraheem","year":"2025","unstructured":"Abdulraheem A, Abujaber B, Ayers L, Al-Zureikat Q, Bashiri K, Almhanni G, et al. Impact of GLP-1 receptor agonists on upper gastrointestinal endoscopy: an updated systematic review and meta-analysis. Surg Endosc. 2025;39:5135\u201351. https:\/\/doi.org\/10.1007\/s00464-025-11962-4.","journal-title":"Surg Endosc"},{"key":"770_CR74","doi-asserted-by":"publisher","first-page":"102043","DOI":"10.1016\/j.artd.2026.102043","volume":"39","author":"B Wajda","year":"2026","unstructured":"Wajda B, Van Essen D, Martini S, Assadzadeh GE, Sharma R, Werle J. Glucagon-Like Peptide-1 Receptor Agonists in Hip and Knee Arthroplasty: A Comprehensive Systematic Review and Meta-Analysis of Perioperative and Postoperative Outcomes. Arthroplast Today. 2026;39:102043. https:\/\/doi.org\/10.1016\/j.artd.2026.102043.","journal-title":"Arthroplast Today"},{"key":"770_CR75","doi-asserted-by":"publisher","first-page":"e1263","DOI":"10.1097\/CCE.0000000000001263","volume":"7","author":"CG Gmehlin","year":"2025","unstructured":"Gmehlin CG, Nemet M, Rizwan ZM, Ahmad S, Gajic O, Tekin A. Impact of Glucagon-Like Peptide-1 Receptor Agonist Exposure on Gastrointestinal Outcomes Among ICU Patients: A Multicenter Matched Cohort Study. Crit Care Explor. 2025;7:e1263. https:\/\/doi.org\/10.1097\/CCE.0000000000001263.","journal-title":"Crit Care Explor"},{"key":"770_CR76","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.7150\/ijms.128956","volume":"23","author":"Y-T Tseng","year":"2026","unstructured":"Tseng Y-T, Chen C-H, Chou L-P, Chen S-Y, Huang H-Y, Wang J-W, et al. Association of Glucagon-like Peptide-1 Receptor Agonists with Mortality and Aspiration Pneumonia in Patients with Type 2 Diabetes After Gastrostomy: A Target Trial Emulation Study. Int J Med Sci. 2026;23:1444\u201355. https:\/\/doi.org\/10.7150\/ijms.128956.","journal-title":"Int J Med Sci"},{"key":"770_CR77","doi-asserted-by":"publisher","first-page":"S339","DOI":"10.2337\/dc26-S016","volume":"49","author":"16","year":"2026","unstructured":"16. Diabetes Care in the Hospital: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49:S339\u201355. https:\/\/doi.org\/10.2337\/dc26-S016.","journal-title":"Diabetes Care"},{"key":"770_CR78","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1213\/ANE.0000000000007764","volume":"142","author":"S-L Pai","year":"2026","unstructured":"Pai S-L, Nimma SR, Beam WB, VanderWielen BA, Kalagara HK, Bettini LM, et al. Assessment of Gastric Content Using Gastric Ultrasound in Patients on Glucagon-Like Peptide-1 Receptor Agonists Before Anesthesia. Anesth Analg. 2026;142:640\u20139. https:\/\/doi.org\/10.1213\/ANE.0000000000007764.","journal-title":"Anesth Analg"},{"key":"770_CR79","doi-asserted-by":"publisher","first-page":"111091","DOI":"10.1016\/j.jclinane.2023.111091","volume":"87","author":"SQ Silveira","year":"2023","unstructured":"Silveira SQ, da Silva LM, de Campos Vieira Abib A, de Moura DTH, de Moura EGH, Santos LB, et al. Relationship between perioperative semaglutide use and residual gastric content: A retrospective analysis of patients undergoing elective upper endoscopy. J Clin Anesth. 2023;87:111091. https:\/\/doi.org\/10.1016\/j.jclinane.2023.111091.","journal-title":"J Clin Anesth"},{"key":"770_CR80","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1111\/den.70016","volume":"37","author":"H Hisada","year":"2025","unstructured":"Hisada H, Tsuji Y, Kubota D, Miura Y, Mizutani H, Ohki D, et al. Impact of Glucagon-Like Peptide-1 Receptor Agonists on Retained Gastric Contents During Esophagogastroduodenoscopy: A Propensity Score-Matched Study. Dig Endosc Off J Japan Gastroenterol Endosc Soc. 2025;37:1340\u20137. https:\/\/doi.org\/10.1111\/den.70016.","journal-title":"Dig Endosc Off J Japan Gastroenterol Endosc Soc"},{"key":"770_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2025.09.017","author":"B Saha","year":"2025","unstructured":"Saha B, Kamalumpundi V, Codipilly DC. GLP1 and GIP Receptor Agonists: Effects on the Gastrointestinal Tract and Management Strategies for Primary Care Physicians. Mayo Clin Proc. 2025. https:\/\/doi.org\/10.1016\/j.mayocp.2025.09.017.","journal-title":"Mayo Clin Proc"},{"key":"770_CR82","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/dom.12824","volume":"19","author":"K Bettge","year":"2017","unstructured":"Bettge K, Kahle M, Abd El Aziz MS, Meier JJ, Nauck MA. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials. Diabetes Obes Metab. 2017;19:336\u201347. https:\/\/doi.org\/10.1111\/dom.12824.","journal-title":"Diabetes Obes Metab"},{"key":"770_CR83","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s12020-025-04494-3","volume":"91","author":"B Joy","year":"2026","unstructured":"Joy B, Ramsamooj A, Ibrahim S, Wen J, Hsu N, Frezza E. Exploring the rates of Gastrointestinal adverse effects among five GLP-1 receptor agonists: A systematic review and Meta-Analysis of randomized controlled trials. Endocrine. 2026;91:23. https:\/\/doi.org\/10.1007\/s12020-025-04494-3.","journal-title":"Endocrine"},{"key":"770_CR84","doi-asserted-by":"publisher","first-page":"525","DOI":"10.4093\/dmj.2025.0242","volume":"49","author":"JA Kim","year":"2025","unstructured":"Kim JA, Yoo HJ. Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning. Diabetes Metab J. 2025;49:525\u201341. https:\/\/doi.org\/10.4093\/dmj.2025.0242.","journal-title":"Diabetes Metab J"},{"key":"770_CR85","doi-asserted-by":"publisher","first-page":"1149328","DOI":"10.3389\/fendo.2023.1149328","volume":"14","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Zhang Q, Tan Y, Chen Y, Zhou X, Liu S, et al. GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis. Front Endocrinol (Lausanne). 2023;14:1149328. https:\/\/doi.org\/10.3389\/fendo.2023.1149328.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"770_CR86","doi-asserted-by":"publisher","first-page":"584175","DOI":"10.2147\/DMSO.S584175","volume":"19","author":"N Y\u0131lmaz","year":"2026","unstructured":"Y\u0131lmaz N, Bastemir M. Gastrointestinal Adverse Effects of GLP-1 and Dual GLP-1\/GIP Receptor Agonists: A Comprehensive Update in Diabetic and Obese Populations. Diabetes Metab Syndr Obes. 2026;19:584175. https:\/\/doi.org\/10.2147\/DMSO.S584175.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"770_CR87","doi-asserted-by":"publisher","unstructured":"Jalleh RJ, Talley NJ, Horowitz M, Nauck MA. The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications. J Clin Invest. 2026;136. https:\/\/doi.org\/10.1172\/JCI194740.","DOI":"10.1172\/JCI194740"},{"key":"770_CR88","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.2147\/DMSO.S494919","volume":"17","author":"S Gentinetta","year":"2024","unstructured":"Gentinetta S, Sottotetti F, Manuelli M, Cena H. Dietary Recommendations for the Management of Gastrointestinal Symptoms in Patients Treated with GLP-1 Receptor Agonist. Diabetes Metab Syndr Obes. 2024;17:4817\u201324. https:\/\/doi.org\/10.2147\/DMSO.S494919.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"770_CR89","doi-asserted-by":"publisher","unstructured":"Gorgojo-Mart\u00ednez JJ, Mezquita-Raya P, Carretero-G\u00f3mez J, Castro A, Cebri\u00e1n-Cuenca A, de Torres-S\u00e1nchez A, et al. Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. J Clin Med. 2022;12. https:\/\/doi.org\/10.3390\/jcm12010145.","DOI":"10.3390\/jcm12010145"},{"key":"770_CR90","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1053\/j.gastro.2025.06.003","volume":"169","author":"C-H Chiang","year":"2025","unstructured":"Chiang C-H, Jaroenlapnopparat A, Colak SC, Yu C-C, Xanthavanij N, Wang T-H, et al. Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis. Gastroenterology. 2025;169:1268\u201381. https:\/\/doi.org\/10.1053\/j.gastro.2025.06.003.","journal-title":"Gastroenterology"},{"key":"770_CR91","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1136\/gutjnl-2023-329651","volume":"73","author":"BD Liu","year":"2024","unstructured":"Liu BD, Udemba SC, Liang K, Tarabichi Y, Hill H, Fass R, et al. Shorter-acting glucagon-like peptide-1 receptor agonists are associated with increased development of gastro-oesophageal reflux disease and its complications in patients with type 2 diabetes mellitus: a population-level retrospective matched cohort study. Gut. 2024;73:246\u201354. https:\/\/doi.org\/10.1136\/gutjnl-2023-329651.","journal-title":"Gut"},{"key":"770_CR92","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.7326\/ANNALS-24-03420","volume":"178","author":"Y Noh","year":"2025","unstructured":"Noh Y, Yin H, Yu OHY, Bitton A, Azoulay L. Glucagon-Like Peptide-1 Receptor Agonists and Risk for Gastroesophageal Reflux Disease in Patients With Type 2 Diabetes: A Population-Based Cohort Study. Ann Intern Med. 2025;178:1268\u201378. https:\/\/doi.org\/10.7326\/ANNALS-24-03420.","journal-title":"Ann Intern Med"},{"key":"770_CR93","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","volume":"11","author":"TD Filippatos","year":"2014","unstructured":"Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse Effects of GLP-1 Receptor Agonists. Rev Diabet Stud. 2014;11:202\u201330. https:\/\/doi.org\/10.1900\/RDS.2014.11.202.","journal-title":"Rev Diabet Stud"},{"key":"770_CR94","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","volume":"182","author":"L He","year":"2022","unstructured":"He L, Wang J, Ping F, Yang N, Huang J, Li Y, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Intern Med. 2022;182:513\u20139. https:\/\/doi.org\/10.1001\/jamainternmed.2022.0338.","journal-title":"JAMA Intern Med"},{"key":"770_CR95","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.2337\/dc25-1840","volume":"48","author":"YE Fang","year":"2025","unstructured":"Fang YE, Paik JM, Ortega-Montiel J, Tesfaye H, Wexler DJ, Patorno E. Risk of Acute Pancreatitis and Biliary Events After Initiation of Incretin-Based Medications in Patients With Type 2 Diabetes. Diabetes Care. 2025;48:2127\u201337. https:\/\/doi.org\/10.2337\/dc25-1840.","journal-title":"Diabetes Care"},{"key":"770_CR96","doi-asserted-by":"publisher","first-page":"204201882514064","DOI":"10.1177\/20420188251406456","volume":"16","author":"MM Ram\u00edrez-Mej\u00eda","year":"2025","unstructured":"Ram\u00edrez-Mej\u00eda MM, Ponciano-Rodriguez G, Eslam M, M\u00e9ndez-S\u00e1nchez N. GLP-1 receptor agonists and gallbladder disease risk: insights into molecular mechanisms and clinical implications. Ther Adv Endocrinol Metab. 2025;16:20420188251406456. https:\/\/doi.org\/10.1177\/20420188251406456.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"770_CR97","doi-asserted-by":"publisher","first-page":"1509561","DOI":"10.3389\/fphar.2025.1509561","volume":"16","author":"L He","year":"2025","unstructured":"He L, Li J, Cheng X, Luo L, Huang Y. Association between GLP-1 RAs and DPP-4 inhibitors with biliary disorders: pharmacovigilance analysis. Front Pharmacol. 2025;16:1509561. https:\/\/doi.org\/10.3389\/fphar.2025.1509561.","journal-title":"Front Pharmacol"},{"key":"770_CR98","doi-asserted-by":"publisher","first-page":"1557691","DOI":"10.3389\/fphar.2025.1557691","volume":"16","author":"C Tao","year":"2025","unstructured":"Tao C, Zhang Y, Wan T, Zhao W, Chen J, Wang K, et al. Glucagon-like peptide-1 receptor agonist-induced cholecystitis and cholelithiasis: a real-world pharmacovigilance analysis using the FAERS database. Front Pharmacol. 2025;16:1557691. https:\/\/doi.org\/10.3389\/fphar.2025.1557691.","journal-title":"Front Pharmacol"},{"key":"770_CR99","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","volume":"141","author":"M Elashoff","year":"2011","unstructured":"Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141:150\u20136. https:\/\/doi.org\/10.1053\/j.gastro.2011.02.018.","journal-title":"Gastroenterology"},{"key":"770_CR100","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1001\/jamainternmed.2013.2720","volume":"173","author":"S Singh","year":"2013","unstructured":"Singh S, Chang H-Y, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013;173:534\u20139. https:\/\/doi.org\/10.1001\/jamainternmed.2013.2720.","journal-title":"JAMA Intern Med"},{"key":"770_CR101","doi-asserted-by":"publisher","first-page":"103363","DOI":"10.1016\/j.eclinm.2025.103363","volume":"86","author":"A Moiz","year":"2025","unstructured":"Moiz A, Filion KB, Tsoukas MA, Yu OHY, Peters TM, Eisenberg MJ. The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions. EClinicalMedicine. 2025;86:103363. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103363.","journal-title":"EClinicalMedicine"},{"key":"770_CR102","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1001\/jama.2023.19574","volume":"330","author":"M Sodhi","year":"2023","unstructured":"Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA. 2023;330:1795\u20137. https:\/\/doi.org\/10.1001\/jama.2023.19574.","journal-title":"JAMA"},{"key":"770_CR103","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40200-024-01552-x","volume":"24","author":"JH Gu","year":"2025","unstructured":"Gu JH, Samarneh M. Dose-dependent pancreatitis risk associated with GLP-1 agonists. J Diabetes Metab Disord. 2025;24:33. https:\/\/doi.org\/10.1007\/s40200-024-01552-x.","journal-title":"J Diabetes Metab Disord"},{"key":"770_CR104","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.pan.2026.03.021","volume":"26","author":"O Benny","year":"2026","unstructured":"Benny O, Agarwal A, Alecock H, Subramani RG, Pawar A, Shams Z, et al. Dose-response analysis of tirzepatide and acute pancreatitis: An international systematic review and quantitative meta-analysis of randomised trials. Pancreatol Off J Int Assoc Pancreatol [et Al]. 2026;26:552\u201365. https:\/\/doi.org\/10.1016\/j.pan.2026.03.021.","journal-title":"Pancreatol Off J Int Assoc Pancreatol [et Al]"},{"key":"770_CR105","doi-asserted-by":"publisher","first-page":"G26","DOI":"10.1152\/ajpgi.00293.2015","volume":"310","author":"Y Hou","year":"2016","unstructured":"Hou Y, Ernst SA, Heidenreich K, Williams JA. Glucagon-like peptide-1 receptor is present in pancreatic acinar cells and regulates amylase secretion through cAMP. Am J Physiol Gastrointest Liver Physiol. 2016;310:G26\u201333. https:\/\/doi.org\/10.1152\/ajpgi.00293.2015.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"770_CR106","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.2337\/db09-0626","volume":"58","author":"JA Koehler","year":"2009","unstructured":"Koehler JA, Baggio LL, Lamont BJ, Ali S, Drucker DJ. Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes. 2009;58:2148\u201361. https:\/\/doi.org\/10.2337\/db09-0626.","journal-title":"Diabetes"},{"key":"770_CR107","doi-asserted-by":"publisher","first-page":"424","DOI":"10.14309\/ajg.0000000000003525","volume":"121","author":"LM Nieto","year":"2026","unstructured":"Nieto LM, Martinez J, Narvaez SI, Ko D, Kim DH, Vega KJ, et al. Glucagon-Like Peptide-1 Receptor Agonists Use Does Not Increase the Risk for Acute Pancreatitis and Is Associated With Lower Complications in Patients With Type 2 Diabetes Who Develop Acute Pancreatitis: A Multicenter Analysis. Am J Gastroenterol. 2026;121:424\u201331. https:\/\/doi.org\/10.14309\/ajg.0000000000003525.","journal-title":"Am J Gastroenterol"},{"key":"770_CR108","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1038\/s41366-025-01859-6","volume":"49","author":"A Ismaiel","year":"2025","unstructured":"Ismaiel A, Scarlata GGM, Boitos I, Leucuta D-C, Popa S-L, Al Srouji N, et al. Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis. Int J Obes (Lond). 2025;49:1946\u201357. https:\/\/doi.org\/10.1038\/s41366-025-01859-6.","journal-title":"Int J Obes (Lond)"},{"key":"770_CR109","doi-asserted-by":"publisher","first-page":"e70113","DOI":"10.1002\/edm2.70113","volume":"8","author":"J Wen","year":"2025","unstructured":"Wen J, Nadora D, Bernstein E, How-Volkman C, Truong A, Joy B, et al. Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Endocrinol Diabetes Metab. 2025;8:e70113. https:\/\/doi.org\/10.1002\/edm2.70113.","journal-title":"Endocrinol Diabetes Metab"},{"key":"770_CR110","doi-asserted-by":"publisher","unstructured":"Ayoub M, Chela H, Amin N, Hunter R, Anwar J, Tahan V, et al. Pancreatitis Risk Associated with GLP-1 Receptor Agonists, Considered as a Single Class, in a Comorbidity-Free Subgroup of Type 2 Diabetes Patients in the United States: A Propensity Score-Matched Analysis. J Clin Med. 2025;14. https:\/\/doi.org\/10.3390\/jcm14030944.","DOI":"10.3390\/jcm14030944"},{"key":"770_CR111","doi-asserted-by":"publisher","first-page":"103116","DOI":"10.1016\/j.dsx.2024.103116","volume":"18","author":"M Nassar","year":"2024","unstructured":"Nassar M, Nassar O, Abosheaishaa H, Misra A. Decreased risk of recurrent acute pancreatitis with semaglutide and tirzepatide in people with type 2 diabetes or obesity with a history of acute pancreatitis: A propensity matched global federated TriNetX database-based retrospective cohort study. Diabetes Metab Syndr. 2024;18:103116. https:\/\/doi.org\/10.1016\/j.dsx.2024.103116.","journal-title":"Diabetes Metab Syndr"},{"key":"770_CR112","doi-asserted-by":"publisher","first-page":"e70116","DOI":"10.1002\/dmrr.70116","volume":"42","author":"B Calvarysky","year":"2026","unstructured":"Calvarysky B, Gal Y, Kushnir S, Turjeman A, Shochat T, Dotan I, et al. Glucagon-Like Peptide-1 Analogues and the Risk of Recurrent Pancreatitis in Diabetic Patients With History of Pancreatitis or Elevated Lipase: Retrospective Cohort Analysis. Diabetes Metab Res Rev. 2026;42:e70116. https:\/\/doi.org\/10.1002\/dmrr.70116.","journal-title":"Diabetes Metab Res Rev"},{"key":"770_CR113","doi-asserted-by":"publisher","first-page":"111806","DOI":"10.1016\/j.diabres.2024.111806","volume":"215","author":"LD Lomeli","year":"2024","unstructured":"Lomeli LD, Kodali AM, Tsushima Y, Mehta AE, Pantalone KM. The incidence of acute pancreatitis with GLP-1 receptor agonist therapy in individuals with a known history of pancreatitis. Diabetes Res Clin Pract. 2024;215:111806. https:\/\/doi.org\/10.1016\/j.diabres.2024.111806.","journal-title":"Diabetes Res Clin Pract"},{"key":"770_CR114","doi-asserted-by":"publisher","first-page":"e104376","DOI":"10.7759\/cureus.104376","volume":"18","author":"S Rallabandi","year":"2026","unstructured":"Rallabandi S, Sharma M, Kosuru K, Kashyap R. A Rare Case of Semaglutide-Associated Small Bowel Obstruction Complicated by Acute Kidney Injury Requiring Dialysis. Cureus. 2026;18:e104376. https:\/\/doi.org\/10.7759\/cureus.104376.","journal-title":"Cureus"},{"key":"770_CR115","doi-asserted-by":"publisher","first-page":"e73085","DOI":"10.1002\/ccr3.73085","volume":"14","author":"T Shimada","year":"2026","unstructured":"Shimada T, Nose Y, Tojima H, Maehata T, Kato A. Tirzepatide-Induced Functional Small Bowel Obstruction in a Surgically Na\u00efve Patient: A Case Report. Clin Case Rep. 2026;14:e73085. https:\/\/doi.org\/10.1002\/ccr3.73085.","journal-title":"Clin Case Rep"},{"key":"770_CR116","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.therap.2020.02.024","volume":"75","author":"B Gudin","year":"2020","unstructured":"Gudin B, Ladhari C, Robin P, Laroche M-L, Babai S, Hillaire-Buys D, et al. Incretin-based drugs and intestinal obstruction: A pharmacovigilance study. Therapie. 2020;75:641\u20137. https:\/\/doi.org\/10.1016\/j.therap.2020.02.024.","journal-title":"Therapie"},{"key":"770_CR117","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s40261-022-01202-1","volume":"42","author":"T Wu","year":"2022","unstructured":"Wu T, Zhang Y, Shi Y, Yu K, Zhao M, Liu S, et al. Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Study Based on the US FDA Adverse Event Reporting System Database. Clin Drug Investig. 2022;42:965\u201375. https:\/\/doi.org\/10.1007\/s40261-022-01202-1.","journal-title":"Clin Drug Investig"},{"key":"770_CR118","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1016\/j.apsb.2023.02.020","volume":"13","author":"J Lu","year":"2023","unstructured":"Lu J, Liu H, Zhou Q, Wang M-W, Li Z. A potentially serious adverse effect of GLP-1 receptor agonists. Acta Pharm Sin B. 2023;13:2291\u20133. https:\/\/doi.org\/10.1016\/j.apsb.2023.02.020.","journal-title":"Acta Pharm Sin B"},{"key":"770_CR119","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1007\/s13668-022-00433-0","volume":"11","author":"D Kounatidis","year":"2022","unstructured":"Kounatidis D, Vallianou NG, Tsilingiris D, Christodoulatos GS, Geladari E, Stratigou T, et al. Therapeutic Potential of GLP-2 Analogs in Gastrointestinal Disorders: Current Knowledge, Nutritional Aspects, and Future Perspectives. Curr Nutr Rep. 2022;11:618\u201342. https:\/\/doi.org\/10.1007\/s13668-022-00433-0.","journal-title":"Curr Nutr Rep"},{"key":"770_CR120","doi-asserted-by":"publisher","first-page":"7494","DOI":"10.1111\/dom.70963","volume":"28","author":"W Alkabbani","year":"2026","unstructured":"Alkabbani W, Crisafulli S, Paik JM, Tavakkoli A, Bykov K, Glynn RJ, et al. Glucagon-Like Peptide-1 Based Therapies and the Risk of Severe Gastrointestinal Motility Adverse Events: A Cohort Study. Diabetes Obes Metab. 2026;28:7494\u2013504. https:\/\/doi.org\/10.1111\/dom.70963.","journal-title":"Diabetes Obes Metab"},{"key":"770_CR121","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1080\/14740338.2025.2465870","volume":"25","author":"L Alfehaid","year":"2026","unstructured":"Alfehaid L, Alyami M, Almohareb S, Alshaya O, Almutairi A. Evaluating bowel obstruction and ileus events in patients on GLP-1 receptor agonists: a systematic review and meta-analysis. Expert Opin Drug Saf. 2026;25:1057\u201365. https:\/\/doi.org\/10.1080\/14740338.2025.2465870.","journal-title":"Expert Opin Drug Saf"},{"key":"770_CR122","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1093\/ibd\/izae276","volume":"31","author":"J Nielsen","year":"2025","unstructured":"Nielsen J, Friedman S, N\u00f8rg\u00e5rd BM, Knudsen T, Kjeldsen J, Wod M. Glucagon-Like Peptide 1 Receptor Agonists Are Not Associated With an Increased Risk of Ileus or Intestinal Obstruction in Patients with Inflammatory Bowel Disease-A Danish Nationwide Cohort Study. Inflamm Bowel Dis. 2025;31:1961\u20135. https:\/\/doi.org\/10.1093\/ibd\/izae276.","journal-title":"Inflamm Bowel Dis"},{"key":"770_CR123","doi-asserted-by":"publisher","unstructured":"Chen J-J, Hsu C-W, Hung C-M, Suen M-W, Wang H-Y, Yang W-C, et al. Agent- and Dose-Specific Intestinal Obstruction Safety of GLP-1 Receptor Agonists and SGLT2 Inhibitors: A Network Meta-Analysis of Randomized Trials. Int J Mol Sci. 2026;27. https:\/\/doi.org\/10.3390\/ijms27020608.","DOI":"10.3390\/ijms27020608"},{"key":"770_CR124","doi-asserted-by":"publisher","first-page":"e48089","DOI":"10.1097\/MD.0000000000048089","volume":"105","author":"B Yuan","year":"2026","unstructured":"Yuan B, Yang Z, Wang C, Zong G, Qiu J, Feng C, et al. Genetic evidence for a causal protective effect of GLP-1 receptor agonists on paralytic ileus but not on other gastrointestinal events. Med (Baltim). 2026;105:e48089. https:\/\/doi.org\/10.1097\/MD.0000000000048089.","journal-title":"Med (Baltim)"},{"key":"770_CR125","doi-asserted-by":"publisher","first-page":"1032199","DOI":"10.3389\/fendo.2022.1032199","volume":"13","author":"S Dong","year":"2022","unstructured":"Dong S, Sun C. Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data. Front Endocrinol (Lausanne). 2022;13:1032199. https:\/\/doi.org\/10.3389\/fendo.2022.1032199.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"770_CR126","doi-asserted-by":"publisher","first-page":"e70066","DOI":"10.1002\/dmrr.70066","volume":"41","author":"A Fishkin","year":"2025","unstructured":"Fishkin A, Rozenberg A, Schechter M, Sehtman-Shachar DR, Aharon-Hananel G, Leibowitz G, et al. Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists Versus Other Glucose-Lowering Agents in People With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Data. Diabetes Metab Res Rev. 2025;41:e70066. https:\/\/doi.org\/10.1002\/dmrr.70066.","journal-title":"Diabetes Metab Res Rev"},{"key":"770_CR127","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1093\/ndt\/gfaf193","volume":"41","author":"T Sasaki","year":"2026","unstructured":"Sasaki T, Giang SM-L, Wu J, Yokoo T, Gallagher M, Bellomo R, et al. The effect of GLP-1 receptor agonists on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc -. Eur Ren Assoc. 2026;41:681\u201391. https:\/\/doi.org\/10.1093\/ndt\/gfaf193.","journal-title":"Eur Ren Assoc"},{"key":"770_CR128","doi-asserted-by":"publisher","unstructured":"Cooper ME, van Raalte DH. GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity. J Clin Invest. 2025;135. https:\/\/doi.org\/10.1172\/JCI194749.","DOI":"10.1172\/JCI194749"},{"key":"770_CR129","doi-asserted-by":"publisher","unstructured":"Deameh MG, Ramez M, Rowaiee R, Bani Irshid BA, Mohamed H, Abdelshafi A, et al. Effects of glucagon-like peptide-1 receptor agonists on male reproductive hormones, semen parameters, and metabolic outcomes: a systematic review. J Sex Med. 2026;23. https:\/\/doi.org\/10.1093\/jsxmed\/qdaf381.","DOI":"10.1093\/jsxmed\/qdaf381"},{"key":"770_CR130","doi-asserted-by":"publisher","unstructured":"Kounatidis D, Vallianou NG, Rebelos E, Vallianou K, Diakoumopoulou E, Makrilakis K, et al. The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe? Biomolecules. 2025;15. https:\/\/doi.org\/10.3390\/biom15091284.","DOI":"10.3390\/biom15091284"},{"key":"770_CR131","doi-asserted-by":"publisher","unstructured":"Varnum AA, Pozzi E, Deebel NA, Evans A, Eid N, Sadeghi-Nejad H, et al. Impact of GLP-1 Agonists on Male Reproductive Health-A Narrative Review. Med (Kaunas). 2023;60. https:\/\/doi.org\/10.3390\/medicina60010050.","DOI":"10.3390\/medicina60010050"},{"key":"770_CR132","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/S2213-8587(21)00115-7","volume":"9","author":"HS Bajaj","year":"2021","unstructured":"Bajaj HS, Gerstein HC, Rao-Melacini P, Basile J, Colhoun H, Conget I, et al. Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial. Lancet Diabetes Endocrinol. 2021;9:484\u201390. https:\/\/doi.org\/10.1016\/S2213-8587(21)00115-7.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"770_CR133","doi-asserted-by":"publisher","first-page":"1448394","DOI":"10.3389\/fendo.2024.1448394","volume":"15","author":"H An","year":"2024","unstructured":"An H, Xie K, Gan H. Glucagon-like peptide-1 receptor agonists and the risk of erectile dysfunction: a drug target Mendelian randomization study. Front Endocrinol (Lausanne). 2024;15:1448394. https:\/\/doi.org\/10.3389\/fendo.2024.1448394.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"770_CR134","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41443-024-00895-6","volume":"37","author":"C Able","year":"2025","unstructured":"Able C, Liao B, Saffati G, Maremanda A, Applewhite J, Nasrallah AA, et al. Prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: a TriNetX database study. Int J Impot Res. 2025;37:315\u20139. https:\/\/doi.org\/10.1038\/s41443-024-00895-6.","journal-title":"Int J Impot Res"},{"key":"770_CR135","doi-asserted-by":"publisher","first-page":"103857","DOI":"10.1016\/j.eclinm.2026.103857","volume":"94","author":"H Tang","year":"2026","unstructured":"Tang H, Lu Y, Zhang B, Zhang D, Asch DA, Chen Y. GLP-1 receptor agonist and risk of erectile dysfunction in men with type 2 diabetes: a target trial emulation. EClinicalMedicine. 2026;94:103857. https:\/\/doi.org\/10.1016\/j.eclinm.2026.103857.","journal-title":"EClinicalMedicine"},{"key":"770_CR136","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s41443-025-01061-2","volume":"37","author":"A Pourabhari Langroudi","year":"2025","unstructured":"Pourabhari Langroudi A, Chen AL, Basran S, Sommer ER, Stinson J, Cheng Y-S, et al. Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data. Int J Impot Res. 2025;37:661\u20137. https:\/\/doi.org\/10.1038\/s41443-025-01061-2.","journal-title":"Int J Impot Res"},{"key":"770_CR137","doi-asserted-by":"publisher","unstructured":"Abedi MM, Patni MM, Shajahan ANB, Dube R, Khadeeja L, Alabid I, et al. GLP-1 Receptor Agonists, Fertility Restoration, and Reproductive Safety in Women of Reproductive Age: A Narrative Review. J Clin Med. 2026;15. https:\/\/doi.org\/10.3390\/jcm15093204.","DOI":"10.3390\/jcm15093204"},{"key":"770_CR138","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.repbio.2019.07.003","volume":"19","author":"SM Saber","year":"2019","unstructured":"Saber SM, Abd El-Rahman HA. Liraglutide treatment effects on rat ovarian and uterine tissues. Reprod Biol. 2019;19:237\u201344. https:\/\/doi.org\/10.1016\/j.repbio.2019.07.003.","journal-title":"Reprod Biol"},{"key":"770_CR139","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.rbmo.2014.07.009","volume":"29","author":"P Fontoura","year":"2014","unstructured":"Fontoura P, Cardoso MC, de Erthal-Martins A, Werneck MC, Sartorio C, Ramos C. The effects of liraglutide on male fertility: a case report. Reprod Biomed Online. 2014;29:644\u20136. https:\/\/doi.org\/10.1016\/j.rbmo.2014.07.009.","journal-title":"Reprod Biomed Online"},{"key":"770_CR140","doi-asserted-by":"publisher","first-page":"e70163","DOI":"10.1002\/dmrr.70163","volume":"42","author":"N Lee","year":"2026","unstructured":"Lee N, Kim Y, Not All. GLP-1 Receptor Agonists Are Alike: Real-World Evidence of Differential Endocrine and Dermatologic Safety. Diabetes Metab Res Rev. 2026;42:e70163. https:\/\/doi.org\/10.1002\/dmrr.70163.","journal-title":"Diabetes Metab Res Rev"},{"key":"770_CR141","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000006367","author":"C Frey","year":"2026","unstructured":"Frey C, Etminan M. Association of Glucagon-Like Peptide-1 Receptor Agonists With Menstrual Events in Reproductive-Aged Patients. Obstet Gynecol. 2026. https:\/\/doi.org\/10.1097\/AOG.0000000000006367.","journal-title":"Obstet Gynecol"},{"key":"770_CR142","doi-asserted-by":"publisher","first-page":"qfaf047","DOI":"10.1093\/sexmed\/qfaf047","volume":"13","author":"V Visvabharathy","year":"2025","unstructured":"Visvabharathy V, MacPhedran S, Shupp K, King B. Anorgasmia following initiation of GLP-1 agonist. Sex Med. 2025;13:qfaf047. https:\/\/doi.org\/10.1093\/sexmed\/qfaf047.","journal-title":"Sex Med"},{"key":"770_CR143","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1210\/clinem\/dgaf288","volume":"110","author":"JA Wyckoff","year":"2025","unstructured":"Wyckoff JA, Lapolla A, Asias-Dinh BD, Barbour LA, Brown FM, Catalano PM, et al. Preexisting Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline. J Clin Endocrinol Metab. 2025;110:2405\u201352. https:\/\/doi.org\/10.1210\/clinem\/dgaf288.","journal-title":"J Clin Endocrinol Metab"},{"key":"770_CR144","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2026.04.037","author":"J Hakim","year":"2026","unstructured":"Hakim J, Rajesh D, Tello JA. Neonatal and obstetric outcomes following periconceptional exposure to glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis. Am J Obstet Gynecol. 2026. https:\/\/doi.org\/10.1016\/j.ajog.2026.04.037.","journal-title":"Am J Obstet Gynecol"},{"key":"770_CR145","doi-asserted-by":"publisher","first-page":"ojaf056","DOI":"10.1093\/asjof\/ojaf056","volume":"7","author":"G Daneshgaran","year":"2025","unstructured":"Daneshgaran G, Shauly O, Gould DJ. Ozempic Face in Plastic Surgery: A Systematic Review of the Literature on GLP-1 Receptor Agonist Mediated Weight Loss and Analysis of Public Perceptions. Aesthetic Surg J Open Forum. 2025;7:ojaf056. https:\/\/doi.org\/10.1093\/asjof\/ojaf056.","journal-title":"Aesthetic Surg J Open Forum"},{"key":"770_CR146","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/ohn.1209","volume":"173","author":"RK Sharma","year":"2025","unstructured":"Sharma RK, Vittetoe KL, Barna AJ, Takkouche S, Varelas AN, Yang SF, et al. Radiographic Midfacial Volume Changes in Patients on GLP-1 Agonists. Otolaryngol Neck Surg Off J Am Acad Otolaryngol Neck Surg. 2025;173:360\u20136. https:\/\/doi.org\/10.1002\/ohn.1209.","journal-title":"Otolaryngol Neck Surg Off J Am Acad Otolaryngol Neck Surg"},{"key":"770_CR147","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1097\/DSS.0000000000005175","volume":"52","author":"M Firsowicz","year":"2026","unstructured":"Firsowicz M, Kamrani P, Zubair R, Boen M, Dayan SH, Fabi SG. Cutaneous Variations in Stem-Cell Population in Those on GLP1-Receptor Agonists: A Comparative Controlled Study. Dermatol Surg Off Publ Am Soc Dermatol Surg [et Al]. 2026;52:S39\u201344. https:\/\/doi.org\/10.1097\/DSS.0000000000005175.","journal-title":"Dermatol Surg Off Publ Am Soc Dermatol Surg [et Al]"},{"key":"770_CR148","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1007\/s13555-026-01792-0","volume":"16","author":"BM Piraccini","year":"2026","unstructured":"Piraccini BM, Va\u00f1\u00f3-Galv\u00e1n S, Blume-Peytavi U, Ribet V, Mengeaud V. Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes. Dermatol Ther (Heidelb). 2026;16:3345\u201360. https:\/\/doi.org\/10.1007\/s13555-026-01792-0.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"770_CR149","doi-asserted-by":"publisher","first-page":"413","DOI":"10.36849\/JDD.8605","volume":"24","author":"S Daniel","year":"2025","unstructured":"Daniel S, Waggett S, Lyles E, Sagut P, Shamaei Zadeh P, Marcelletti A, et al. A Retrospective Comparative Analysis of Cutaneous Adverse Reactions in GLP-1 Agonist Therapies. J Drugs Dermatol. 2025;24:413\u20135. https:\/\/doi.org\/10.36849\/JDD.8605.","journal-title":"J Drugs Dermatol"},{"key":"770_CR150","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. https:\/\/doi.org\/10.1056\/NEJMoa2206038.","journal-title":"N Engl J Med"},{"key":"770_CR151","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jdin.2026.01.014","volume":"25","author":"SI Vidal","year":"2026","unstructured":"Vidal SI, Akiska YM, Nasseri M, Menta N, Nussbaum D, Cotton CH, et al. Increased risk of hair loss with GLP-1 receptor agonists: A real-world multicenter TrinetX cohort study. JAAD Int. 2026;25:133\u20135. https:\/\/doi.org\/10.1016\/j.jdin.2026.01.014.","journal-title":"JAAD Int"},{"key":"770_CR152","doi-asserted-by":"publisher","first-page":"e70835","DOI":"10.1111\/jocd.70835","volume":"25","author":"Y Argobi","year":"2026","unstructured":"Argobi Y, Jadaan NS, Alshalhoob HB, Alyousef MS, Alotaibi GM, Alwesaibie HS, et al. Predictors and Characteristics of Hair Loss Among Users of GLP-1 Receptor Agonists: A Cross-Sectional Analysis. J Cosmet Dermatol. 2026;25:e70835. https:\/\/doi.org\/10.1111\/jocd.70835.","journal-title":"J Cosmet Dermatol"},{"key":"770_CR153","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1097\/DSS.0000000000005176","volume":"52","author":"N Zarabian","year":"2026","unstructured":"Zarabian N, Farah M, Stines A, Friedman A. The Role of Glucagon-Like Peptide-1 Receptor Agonists in Hair Loss: Clinical Evidence and Proposed Mechanisms. Dermatol Surg Off Publ Am Soc Dermatol Surg [et Al]. 2026;52:S67\u201371. https:\/\/doi.org\/10.1097\/DSS.0000000000005176.","journal-title":"Dermatol Surg Off Publ Am Soc Dermatol Surg [et Al]"},{"key":"770_CR154","doi-asserted-by":"publisher","first-page":"109555","DOI":"10.1016\/j.biopha.2019.109555","volume":"120","author":"L Zhu","year":"2019","unstructured":"Zhu L, Zhou J, Pan Y, Lv J, Liu Y, Yu S, et al. Glucagon-like peptide-1 receptor expression and its functions are regulated by androgen. Biomed Pharmacother. 2019;120:109555. https:\/\/doi.org\/10.1016\/j.biopha.2019.109555.","journal-title":"Biomed Pharmacother"},{"key":"770_CR155","doi-asserted-by":"publisher","first-page":"113333","DOI":"10.1016\/j.diabres.2026.113333","volume":"237","author":"P-L Cheng","year":"2026","unstructured":"Cheng P-L, Chang H-C. Glucagon-like peptide-1 receptor agonists and hair loss: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2026;237:113333. https:\/\/doi.org\/10.1016\/j.diabres.2026.113333.","journal-title":"Diabetes Res Clin Pract"},{"key":"770_CR156","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1111\/dom.70382","volume":"28","author":"S Taj","year":"2026","unstructured":"Taj S, Zuber M, Rashid M, Chhabra M, Undela K, Rawal S, et al. Injection-site and dermatologic reactions associated with glucagon-like peptide-1 receptor agonists: Insights from meta-analysis of randomised controlled trials and real-world evidence. Diabetes Obes Metab. 2026;28:1956\u201371. https:\/\/doi.org\/10.1111\/dom.70382.","journal-title":"Diabetes Obes Metab"},{"key":"770_CR157","doi-asserted-by":"publisher","first-page":"e45181","DOI":"10.7759\/cureus.45181","volume":"15","author":"J Mizumoto","year":"2023","unstructured":"Mizumoto J. Tirzepatide-Induced Injection Site Reaction. Cureus. 2023;15:e45181. https:\/\/doi.org\/10.7759\/cureus.45181.","journal-title":"Cureus"},{"key":"770_CR158","doi-asserted-by":"publisher","first-page":"luae105","DOI":"10.1210\/jcemcr\/luae105","volume":"2","author":"R Moreno-Borque","year":"2024","unstructured":"Moreno-Borque R, Guhl-Mill\u00e1n G, Mera-Carreiro S, Pazos-Guerra M, Cort\u00e9s-Toro JA, L\u00f3pez-Bran E. Delayed Type Hypersensitivity Reaction Induced By Liraglutide With Tolerance to Semaglutide. JCEM Case Rep. 2024;2:luae105. https:\/\/doi.org\/10.1210\/jcemcr\/luae105.","journal-title":"JCEM Case Rep"},{"key":"770_CR159","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s13555-025-01640-7","volume":"16","author":"B Kwiek","year":"2026","unstructured":"Kwiek B, Sieczych J, \u0141ukowska K, Ambroziak M. Improvement of Chronic Spontaneous Urticaria After Glucagon-Like Peptide 1 Receptor Agonist Therapy: Report of Two Cases. Dermatol Ther (Heidelb). 2026;16:1419\u201325. https:\/\/doi.org\/10.1007\/s13555-025-01640-7.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"770_CR160","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1159\/000544023","volume":"11","author":"OM Burke","year":"2025","unstructured":"Burke OM, Sa B, Cespedes DA, Tosti A. Dermatologic Implications of Glucagon-Like Peptide-1 Receptor Agonist Medications. Ski Appendage Disord. 2025;11:416\u201323. https:\/\/doi.org\/10.1159\/000544023.","journal-title":"Ski Appendage Disord"},{"key":"770_CR161","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.7150\/ijms.55421","volume":"18","author":"L Huang","year":"2021","unstructured":"Huang L, Liu Y, Li H, Huang W, Geng R, Tang Z, et al. Bullous Pemphigoid and Diabetes medications: A disproportionality analysis based on the FDA Adverse Event Reporting System. Int J Med Sci. 2021;18:1946\u201352. https:\/\/doi.org\/10.7150\/ijms.55421.","journal-title":"Int J Med Sci"},{"key":"770_CR162","doi-asserted-by":"publisher","first-page":"1801203","DOI":"10.3389\/fendo.2026.1801203","volume":"17","author":"Y-L Chiang","year":"2026","unstructured":"Chiang Y-L, Li T-H, Fang Y-W, Liu Y-F, Wu J, Tsai M-H. Dermatologic outcomes associated with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a large-scale target trial emulation. Front Endocrinol (Lausanne). 2026;17:1801203. https:\/\/doi.org\/10.3389\/fendo.2026.1801203.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"770_CR163","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.1111\/ijd.15863","volume":"61","author":"E Bostan","year":"2022","unstructured":"Bostan E, Akdogan N, Gokoz O. Paradoxical new-onset psoriasiform dermatitis associated with exenatide administration. Int J Dermatol. 2022;61:e112\u20134. https:\/\/doi.org\/10.1111\/ijd.15863.","journal-title":"Int J Dermatol"},{"key":"770_CR164","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jaad.2024.03.021","volume":"91","author":"MM Tran","year":"2024","unstructured":"Tran MM, Mirza FN, Lee AC, Goldbach HS, Libby TJ, Wisco OJ. Dermatologic findings associated with semaglutide use: A scoping review. J Am Acad Dermatol. 2024;91:166\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2024.03.021.","journal-title":"J Am Acad Dermatol"},{"key":"770_CR165","doi-asserted-by":"publisher","unstructured":"Laroche M-L, G\u00e9niaux H, Jardou M. Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review. Eur J Clin Pharmacol. 2026;82. https:\/\/doi.org\/10.1007\/s00228-026-04079-7.","DOI":"10.1007\/s00228-026-04079-7"},{"key":"770_CR166","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000001178","author":"D Haner Wasserstein","year":"2026","unstructured":"Haner Wasserstein D, Whitford T, Whiteson HZ, Frishman WH. Lean Mass Loss in Glucagon-Like Peptide-1\/GIP Therapy: Clinical Implications for Obesity and Cardiovascular Care. Cardiol Rev. 2026. https:\/\/doi.org\/10.1097\/CRD.0000000000001178.","journal-title":"Cardiol Rev"},{"key":"770_CR167","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.amjmed.2026.02.034","volume":"139","author":"RC Shaooli","year":"2026","unstructured":"Shaooli RC. Sarcopenia in the era of GLP-1 receptor agonists: Implications for the internist. Am J Med. 2026;139:1103\u20135. https:\/\/doi.org\/10.1016\/j.amjmed.2026.02.034.","journal-title":"Am J Med"},{"key":"770_CR168","doi-asserted-by":"publisher","first-page":"156113","DOI":"10.1016\/j.metabol.2024.156113","volume":"164","author":"P Karakasis","year":"2025","unstructured":"Karakasis P, Patoulias D, Fragakis N, Mantzoros CS. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis. Metabolism. 2025;164:156113. https:\/\/doi.org\/10.1016\/j.metabol.2024.156113.","journal-title":"Metabolism"},{"key":"770_CR169","doi-asserted-by":"publisher","first-page":"5645","DOI":"10.2147\/DDDT.S531778","volume":"19","author":"Q Ren","year":"2025","unstructured":"Ren Q, Zhi L, Liu H. Semaglutide Therapy and Accelerated Sarcopenia in Older Adults with Type 2 Diabetes: A 24-Month Retrospective Cohort Study. Drug Des Devel Ther. 2025;19:5645\u201352. https:\/\/doi.org\/10.2147\/DDDT.S531778.","journal-title":"Drug Des Devel Ther"},{"key":"770_CR170","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/bcp.70253","volume":"92","author":"R Qaisar","year":"2026","unstructured":"Qaisar R, Khan IU, Rehman AU, Iqbal MS, Ahmad F, Karim A. Semaglutide use is associated with neuromuscular junction degradation in older adults with type II diabetes mellitus. Br J Clin Pharmacol. 2026;92:149\u201361. https:\/\/doi.org\/10.1002\/bcp.70253.","journal-title":"Br J Clin Pharmacol"},{"key":"770_CR171","doi-asserted-by":"publisher","first-page":"e70251","DOI":"10.1002\/jcsm.70251","volume":"17","author":"S Ueta","year":"2026","unstructured":"Ueta S, Niimura T, Goda M, Ishida T, Iwata N, Takeda T, et al. Muscle Atrophy-Related Adverse Events of Antidiabetic Drug Classes: A Pharmacovigilance Analysis Using VigiBase Data. J Cachexia Sarcopenia Muscle. 2026;17:e70251. https:\/\/doi.org\/10.1002\/jcsm.70251.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"770_CR172","doi-asserted-by":"publisher","first-page":"R31","DOI":"10.1093\/ejendo\/lvaf223","volume":"193","author":"A Gonz\u00e1lez-Luis","year":"2025","unstructured":"Gonz\u00e1lez-Luis A, Llinares-Arvelo V, Mart\u00ednez-Alberto CE, Hern\u00e1ndez-Carballo C, Mora-Fern\u00e1ndez C, Navarro-Gonz\u00e1lez JF, et al. Glucagon-like peptide-1 receptor agonists and muscle health: potential role in sarcopenia prevention and treatment. Eur J Endocrinol. 2025;193:R31\u201344. https:\/\/doi.org\/10.1093\/ejendo\/lvaf223.","journal-title":"Eur J Endocrinol"},{"key":"770_CR173","doi-asserted-by":"publisher","first-page":"e70254","DOI":"10.1002\/jcsm.70254","volume":"17","author":"V Old","year":"2026","unstructured":"Old V, Davies M, Denniff M, Choudhary P, Eastley N, Ashford RU, et al. Mitochondrial Adaptations in Skeletal Muscle Following Incretin-Based Therapies: In Vitro. J Cachexia Sarcopenia Muscle. 2026;17:e70254. https:\/\/doi.org\/10.1002\/jcsm.70254.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"770_CR174","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1186\/s13098-025-01877-4","volume":"17","author":"Y Wang","year":"2025","unstructured":"Wang Y, Lan B, Zhang S, Mu Y, Mi J, Yu J, et al. Dionysus or apollo, skeletal muscle mass changes in type 2 diabetes with sarcopenia receiving GLP-1 receptor agonist: systematic review and meta-analysis. Diabetol Metab Syndr. 2025;17:315. https:\/\/doi.org\/10.1186\/s13098-025-01877-4.","journal-title":"Diabetol Metab Syndr"},{"key":"770_CR175","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/S2213-8587(25)00027-0","volume":"13","author":"N Sattar","year":"2025","unstructured":"Sattar N, Neeland IJ, Dahlqvist Leinhard O, Fern\u00e1ndez Land\u00f3 L, Bray R, Linge J, et al. Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol. 2025;13:482\u201393. https:\/\/doi.org\/10.1016\/S2213-8587(25)00027-0.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"770_CR176","doi-asserted-by":"publisher","DOI":"10.1111\/bph.70355","author":"K Prokopidis","year":"2026","unstructured":"Prokopidis K. Glucagon-like peptide-1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions. Br J Pharmacol. 2026. https:\/\/doi.org\/10.1111\/bph.70355.","journal-title":"Br J Pharmacol"},{"key":"770_CR177","doi-asserted-by":"publisher","unstructured":"Vallianou NG, Evangelopoulos AA, Christodoulatos GS, Tantsi I, Mantouvalos N, Chatzis D, et al. Unravelling Sarcopenia in Chronic Kidney Disease: From Pathogenesis to Diagnosis and Therapeutics. Diagnostics (Basel Switzerland). 2026;16. https:\/\/doi.org\/10.3390\/diagnostics16071063.","DOI":"10.3390\/diagnostics16071063"},{"key":"770_CR178","doi-asserted-by":"publisher","first-page":"4428","DOI":"10.1111\/dom.70649","volume":"28","author":"M Jensterle","year":"2026","unstructured":"Jensterle M, Jane\u017e A. Rethinking Muscle Health Assessment in GLP-1-Based Therapies for Obesity: Beyond Lean Mass. Diabetes Obes Metab. 2026;28:4428\u201331. https:\/\/doi.org\/10.1111\/dom.70649.","journal-title":"Diabetes Obes Metab"},{"key":"770_CR179","doi-asserted-by":"publisher","unstructured":"Simsek H, Ucar A. GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia and Sarcopenic Obesity. Curr Nutr Rep. 2026;15. https:\/\/doi.org\/10.1007\/s13668-026-00777-x.","DOI":"10.1007\/s13668-026-00777-x"},{"key":"770_CR180","doi-asserted-by":"publisher","unstructured":"Korus S, Cembrowska-Lech D, K\u0142oda K, Stachowska E. Dietary intake patterns and nutritional adequacy among adults with overweight or obesity treated with GLP-1 or dual GIP\/GLP-1 receptor agonists- preliminary study. J Transl Med. 2026;24. https:\/\/doi.org\/10.1186\/s12967-026-07702-4.","DOI":"10.1186\/s12967-026-07702-4"},{"key":"770_CR181","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.201810","author":"Y Abuetabh","year":"2026","unstructured":"Abuetabh Y, Schmidt MA, Naganuma M, Vaka R, El-Ghiaty MA, Braun S, et al. Semaglutide-induced loss of skeletal muscle mass is blunted by co-administration of ketone esters. JCI Insight. 2026. https:\/\/doi.org\/10.1172\/jci.insight.201810.","journal-title":"JCI Insight"},{"key":"770_CR182","doi-asserted-by":"publisher","first-page":"e105734","DOI":"10.7759\/cureus.105734","volume":"18","author":"LM Canal de Velasco","year":"2026","unstructured":"Canal de Velasco LM, Gonz\u00e1lez Flores JE, Kraus Fischer G, Morales Arteaga JL, Olivares Casas MJ, Alvarez Nava KN, et al. Testosterone Replacement Therapy as a Potential Strategy to Preserve Lean Mass in Men With Persistently Low Serum Testosterone Receiving GLP-1 Receptor Agonists: A Narrative Review. Cureus. 2026;18:e105734. https:\/\/doi.org\/10.7759\/cureus.105734.","journal-title":"Cureus"},{"key":"770_CR183","doi-asserted-by":"publisher","first-page":"263","DOI":"10.11005\/jbm.25.919","volume":"32","author":"J Baik","year":"2025","unstructured":"Baik J, Lee Y-S. Emerging Role of Myostatin Inhibitors in the Management of Glucagon-Like Peptide-1-Associated Sarcopenia and Metabolic Disorders. J Bone Metab. 2025;32:263\u201375. https:\/\/doi.org\/10.11005\/jbm.25.919.","journal-title":"J Bone Metab"},{"key":"770_CR184","doi-asserted-by":"publisher","unstructured":"Kounatidis D, Vallianou NG, Karampela I, Rebelos E, Kouveletsou M, Dalopoulos V, et al. Anti-Diabetic Therapies and Cancer: From Bench to Bedside. Biomolecules. 2024;14. https:\/\/doi.org\/10.3390\/biom14111479.","DOI":"10.3390\/biom14111479"},{"key":"770_CR185","doi-asserted-by":"publisher","first-page":"924168","DOI":"10.1155\/2012\/924168","volume":"2012","author":"W-Y Chiu","year":"2012","unstructured":"Chiu W-Y, Shih S-R, Tseng C-H. A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancer. Exp Diabetes Res. 2012;2012:924168. https:\/\/doi.org\/10.1155\/2012\/924168.","journal-title":"Exp Diabetes Res"},{"key":"770_CR186","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/dom.15382","volume":"26","author":"GA Silverii","year":"2024","unstructured":"Silverii GA, Monami M, Gallo M, Ragni A, Prattichizzo F, Renzelli V, et al. Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2024;26:891\u2013900. https:\/\/doi.org\/10.1111\/dom.15382.","journal-title":"Diabetes Obes Metab"},{"key":"770_CR187","doi-asserted-by":"publisher","first-page":"216","DOI":"10.7326\/ANNALS-25-02237","volume":"179","author":"A Ko","year":"2026","unstructured":"Ko A, Chang Y-C, Bahar F, Wang TH, Xanthavanij N, Yu C-C, et al. Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists: A Systematic Review and Meta-analysis. Ann Intern Med. 2026;179:216\u201329. https:\/\/doi.org\/10.7326\/ANNALS-25-02237.","journal-title":"Ann Intern Med"},{"key":"770_CR188","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1111\/dom.16504","volume":"27","author":"L Duchemin","year":"2025","unstructured":"Duchemin L, Morice A, Morice P-M, Bernardeau C, Alexandre J, Fedrizzi S, et al. Risk of thyroid cancer related to glucagon-like peptide-1 receptor agonists: A systematic review with meta-analysis of harms of randomized controlled trials. Diabetes Obes Metab. 2025;27:4607\u201310. https:\/\/doi.org\/10.1111\/dom.16504.","journal-title":"Diabetes Obes Metab"},{"key":"770_CR189","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1111\/dme.12301","volume":"30","author":"REJ Ryder","year":"2013","unstructured":"Ryder REJ. The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits. Diabet Med. 2013;30:1148\u201355. https:\/\/doi.org\/10.1111\/dme.12301.","journal-title":"Diabet Med"},{"key":"770_CR190","doi-asserted-by":"publisher","unstructured":"Lauri G, Arcidiacono PG, Facciorusso A, Capurso G, Tacelli M. Glucagon-like Peptide-1 receptor agonists are not associated with increased risk of pancreatic cancer: A systematic review and meta-analysis. Pancreatology. 2026;S1424\u20133903. https:\/\/doi.org\/10.1016\/j.pan.2026.04.005.","DOI":"10.1016\/j.pan.2026.04.005"},{"key":"770_CR191","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/jnci\/djae260","volume":"117","author":"L Wang","year":"2025","unstructured":"Wang L, Wang Q, Li L, Kaelber DC, Xu R. Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data. J Natl Cancer Inst. 2025;117:476\u201385. https:\/\/doi.org\/10.1093\/jnci\/djae260.","journal-title":"J Natl Cancer Inst"},{"key":"770_CR192","doi-asserted-by":"publisher","first-page":"113158","DOI":"10.1016\/j.diabres.2026.113158","volume":"234","author":"YA Ateiwi","year":"2026","unstructured":"Ateiwi YA, Mahmood R, Wong HJ, Low CE, Yau CE, Lee ARY, Bin, et al. Glucagon-like peptide-1 receptor agonists and the risk of obesity-related cancers: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2026;234:113158. https:\/\/doi.org\/10.1016\/j.diabres.2026.113158.","journal-title":"Diabetes Res Clin Pract"},{"key":"770_CR193","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1097\/JS9.0000000000003450","volume":"112","author":"C-M Hung","year":"2026","unstructured":"Hung C-M, Zeng B-Y, Hsu C-W, Chen P-H, Sun C-K, Carvalho AF, et al. The different colorectal tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 68 randomized controlled trials. Int J Surg. 2026;112:443\u201359. https:\/\/doi.org\/10.1097\/JS9.0000000000003450.","journal-title":"Int J Surg"},{"key":"770_CR194","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1111\/dom.16489","volume":"27","author":"GA Silverii","year":"2025","unstructured":"Silverii GA, Marinelli C, Bettarini C, Del Vescovo GG, Monami M, Mannucci E. GLP-1 receptor agonists and the risk for cancer: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2025;27:4454\u201368. https:\/\/doi.org\/10.1111\/dom.16489.","journal-title":"Diabetes Obes Metab"},{"key":"770_CR195","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41571-026-01135-0","volume":"23","author":"E Mannucci","year":"2026","unstructured":"Mannucci E, Dicembrini I. Glucagon-like peptide 1 receptor agonists and cancer risk: the good, the bad and the unknown. Nat Rev Clin Oncol. 2026;23:459\u201370. https:\/\/doi.org\/10.1038\/s41571-026-01135-0.","journal-title":"Nat Rev Clin Oncol"},{"key":"770_CR196","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40264-023-01392-3","volume":"47","author":"B Calvarysky","year":"2024","unstructured":"Calvarysky B, Dotan I, Shepshelovich D, Leader A, Cohen TD. Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review. Drug Saf. 2024;47:439\u201351. https:\/\/doi.org\/10.1007\/s40264-023-01392-3.","journal-title":"Drug Saf"},{"key":"770_CR197","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-026-61582-8","author":"N Uysal","year":"2026","unstructured":"Uysal N, Horoz E, Gungor M, Timarci I, Sozmen MK, Karadas B, et al. Pregnancy outcomes following maternal GLP-1 receptor agonist exposure: a systematic review and meta-analysis. Sci Rep. 2026. https:\/\/doi.org\/10.1038\/s41598-026-61582-8.","journal-title":"Sci Rep"},{"key":"770_CR198","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1136\/jim-2021-001952","volume":"70","author":"G Singh","year":"2022","unstructured":"Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med Off Publ Am Fed Clin Res. 2022;70:5\u201313. https:\/\/doi.org\/10.1136\/jim-2021-001952.","journal-title":"J Investig Med Off Publ Am Fed Clin Res"},{"key":"770_CR199","doi-asserted-by":"publisher","first-page":"e49305","DOI":"10.2196\/49305","volume":"26","author":"A Backman","year":"2024","unstructured":"Backman A, Roll-Pettersson L, Mellblom A, Norman-Claesson E, Sundqvist E, Zander E, et al. Internet-Delivered Psychoeducation (SCOPE) for Transition-Aged Autistic Youth: Pragmatic Randomized Controlled Trial. J Med Internet Res. 2024;26:e49305. https:\/\/doi.org\/10.2196\/49305.","journal-title":"J Med Internet Res"},{"key":"770_CR200","doi-asserted-by":"publisher","unstructured":"DePietro R, Bertarelli I, Zink CM, Canfield SM, Smith J, McElroy JA. Considering Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) for Weight Loss: Insights from a Pragmatic Mixed-Methods Study of Patient Beliefs and Barriers. Healthc (Basel Switzerland). 2026;14. https:\/\/doi.org\/10.3390\/healthcare14020186.","DOI":"10.3390\/healthcare14020186"},{"key":"770_CR201","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13098-025-02051-6","volume":"18","author":"ET Trexler","year":"2026","unstructured":"Trexler ET. Methodological and statistical errors distort the effects of glucagon-like peptide-1 receptor agonist drugs on body composition in patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2026;18:24. https:\/\/doi.org\/10.1186\/s13098-025-02051-6.","journal-title":"Diabetol Metab Syndr"},{"key":"770_CR202","doi-asserted-by":"publisher","unstructured":"Xu S. Safety Signals of GLP-1 Receptor Agonists: A Multi-Method Pharmacovigilance Analysis of FAERS (2018\u20132025) With Sensitivity-Stratified Prioritisation, Notoriety-Bias Assessment, and Cross-Database Validation. Diabetes Obes Metab. 202X. https:\/\/doi.org\/10.1111\/dom.71138.","DOI":"10.1111\/dom.71138"},{"key":"770_CR203","doi-asserted-by":"publisher","first-page":"118163","DOI":"10.1016\/j.ejmech.2025.118163","volume":"300","author":"X He","year":"2025","unstructured":"He X, Zhao Z, Sun Y, Jiang X. Unraveling the safety profile of GLP-1 receptor agonists: Mechanistic insights with a focus on semaglutide. Eur J Med Chem. 2025;300:118163. https:\/\/doi.org\/10.1016\/j.ejmech.2025.118163.","journal-title":"Eur J Med Chem"},{"key":"770_CR204","doi-asserted-by":"publisher","DOI":"10.3390\/ph19060876","author":"IR Popa Ilie","year":"2026","unstructured":"Popa Ilie IR, Ghibu S, Butuca A, Dobrea CM, Frum A, Homorodean C, et al. Pharmaceuticals (Basel). 2026;19. https:\/\/doi.org\/10.3390\/ph19060876. Incretin-Based Drugs for Obesity: Common and Drug-Specific Reporting Patterns of Adverse Drug Reactions-A Comparative Disproportionality Analysis Using EudraVigilance Reports Integrating SmPC Data."},{"key":"770_CR205","doi-asserted-by":"publisher","first-page":"102661","DOI":"10.1016\/j.eclinm.2024.102661","volume":"73","author":"H Moll","year":"2024","unstructured":"Moll H, Frey E, Gerber P, Geidl B, Kaufmann M, Braun J, et al. GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit-harm modelling study. EClinicalMedicine. 2024;73:102661. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102661.","journal-title":"EClinicalMedicine"},{"key":"770_CR206","doi-asserted-by":"publisher","first-page":"103991","DOI":"10.1016\/j.eclinm.2026.103991","volume":"96","author":"A Moiz","year":"2026","unstructured":"Moiz A, Peters TM, Tsoukas MA, Yu OHY, Filion KB, Eisenberg MJ. Balancing the benefits and risks of GLP-1 receptor agonists: a clinical guide for shared decision-making. EClinicalMedicine. 2026;96:103991. https:\/\/doi.org\/10.1016\/j.eclinm.2026.103991.","journal-title":"EClinicalMedicine"},{"key":"770_CR207","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2026.1498","author":"J Zontag","year":"2026","unstructured":"Zontag J, Zontag N. Smell and Taste Disturbances Among Glucagon-Like Peptide-1 Receptor Agonist Users. JAMA Otolaryngol Head Neck Surg. 2026. https:\/\/doi.org\/10.1001\/jamaoto.2026.1498.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"770_CR208","doi-asserted-by":"publisher","first-page":"100463","DOI":"10.1016\/j.metop.2026.100463","volume":"30","author":"IG Lempesis","year":"2026","unstructured":"Lempesis IG, Dalamaga M. Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies. Metab Open. 2026;30:100463. https:\/\/doi.org\/10.1016\/j.metop.2026.100463.","journal-title":"Metab Open"},{"key":"770_CR209","doi-asserted-by":"publisher","first-page":"100449","DOI":"10.1016\/j.metop.2026.100449","volume":"29","author":"VE Georgakopoulou","year":"2026","unstructured":"Georgakopoulou VE, Dalamaga M. GLP-1 receptor agonists and obstructive lung disease: Beyond metabolic control to respiratory outcomes. Metab Open. 2026;29:100449. https:\/\/doi.org\/10.1016\/j.metop.2026.100449.","journal-title":"Metab Open"},{"key":"770_CR210","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2600751","author":"CW le Roux","year":"2026","unstructured":"le Roux CW, Wharton S, Startseva E, Kloer IM, Hussain SA, Unseld A, et al. Survodutide Once Weekly for the Treatment of Adults with Obesity. N Engl J Med. 2026. https:\/\/doi.org\/10.1056\/NEJMoa2600751.","journal-title":"N Engl J Med"}],"container-title":["Current Obesity Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-026-00770-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13679-026-00770-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-026-00770-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T05:51:18Z","timestamp":1792561878000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13679-026-00770-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":210,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["770"],"URL":"https:\/\/doi.org\/10.1007\/s13679-026-00770-z","relation":{"references":[{"id-type":"doi","id":"10.3390\/ph17020147","asserted-by":"subject"},{"id-type":"doi","id":"10.3390\/ph19060876","asserted-by":"subject"}]},"ISSN":["2162-4968"],"issn-type":[{"value":"2162-4968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"11 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests..","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors of this article conducted any research using either human or animal subjects","order":4,"name":"Ethics","label":"Animal and Human Rights and Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Institutional Review Board Statement","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"91"}}